Background and Purpose-The acute stroke literature lacks a standard convention regarding the critical end point of revascularization. Two distinct parameters may be clinically important: (1) recanalization of the primary arterial occlusive lesion (AOL) and (2) global reperfusion of the distal vascular bed. We sought to determine their relationship in the Interventional Management of Stroke (IMS) Phase I trial of combined intravenous (IV) and intraarterial (IA) recombinant tissue plasminogen activator. Methods-Sixty-one angiograms were reanalyzed using recanalization and reperfusion scores. The AOL Score was defined as: 0ϭno recanalization of the primary occlusion, Iϭincomplete or partial recanalization of the primary occlusion with no distal flow, IIϭincomplete or partial recanalization of the primary occlusion with distal flow, or IIIϭcomplete recanalization of the primary occlusion with distal flow. The Thrombolysis in Myocardial Infarction (TIMI) Score was defined as: 0ϭno perfusion, 1ϭperfusion past the initial occlusion but no distal branch filling, 2ϭperfusion and incomplete or slow distal branch filling, or 3ϭfull perfusion with filling of all distal branches. We compared the 2 scores with one another and with good clinical outcome (modified Rankin Score zero to 2). Key Words: acute Rx Ⅲ acute stroke Ⅲ interventional neuroradiology T hrombolytic revascularization is the only proven, effective way to reverse neurologic deficit in acute ischemic stroke. 1 Newer revascularization strategies are often assessed, at least in part, based on their ability to restore flow. In addition, the U.S. Food and Drug Administration (FDA) assesses devices for revascularization according to their ability to restore blood flow. 2 However, despite attempts to define reporting standards for thrombolysis trials, 3 the acute stroke literature currently lacks a standard convention for describing this critical end point. Trials, studies, and case series have used the terms "recanalization" and "reperfusion," or sometimes both interchangeably, to describe revascularization. Moreover, definitions of each term vary. Results-AOLTwo distinct parameters that may be critical in the assessment of revascularization are (1) recanalization of the primary arterial occlusive lesion (AOL) and (2) global reperfusion of the distal vascular bed. Distinguishing between these parameters may be clinically important. For example, an artery may be completely recanalized, but distal clot embolization may limit distal reperfusion. This may limit significant neurologic recovery and could theoretically increase the risk of hemorrhage as a result of local hyperperfusion in ischemic brain regions. On the other hand, distal reperfusion may be achieved, but the artery may have incomplete recanalization (ie, residual clot at the primary occlusive site) predisposing to a higher rate of reocclusion with subsequent clinical deterioration. 4 Drugs, devices, or combinations may differ in their ability to achieve and maintain recanalization and reperfusion.Heterogeneo...
in each case. Asepsis cannot be maintained and prompt healing will occur only when the tissue is prop« rly nourished and gently handled. Rough handling or lack of consideration for the nutrition of the Haps will result disastrously no matter how accurately the defect is covered. The flaps should always be taken a little larger than seems necessary, particularly in remedying deformities resulting from hums. No dressing should he placed on these wounds unless there is considerable bleeding; in this case a dry compress may be used for twenty-four hours and should then be removed. The raw surface should he dusted with boric acid powder,
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.